{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-MHZDI69C/af77058e-2ed4-498c-b19b-4738a0bb50ad/PDF","dcterms:extent":"324 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-MHZDI69C/b8b4088d-d6ca-4e83-8aca-2cfb7c123493/TEXT","dcterms:extent":"30 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-MHZDI69C","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2016","dc:creator":["Devjak Novak, Sabina","Košir, Darjan","Vrečer, Franc"],"dc:format":[{"@xml:lang":"sl","#text":"številka:4"},{"@xml:lang":"sl","#text":"letnik:67"},{"@xml:lang":"sl","#text":"str. 273-280"}],"dc:identifier":["ISSN:0014-8229","COBISSID:4101745","URN:URN:NBN:SI:doc-MHZDI69C"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"en","#text":"drug"},{"@xml:lang":"sl","#text":"farmacevtski pripravki"},{"@xml:lang":"sl","#text":"funkcionalnost pomožnih snovi"},{"@xml:lang":"sl","#text":"hipromeloza"},{"@xml:lang":"sl","#text":"lastnosti pomožnih snovi"},{"@xml:lang":"sl","#text":"pomožne snovi"},{"@xml:lang":"sl","#text":"zdravila"},{"@rdf:resource":"http://www.wikidata.org/entity/Q12140"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"S funkcionalnostjo povezane lastnosti hipromeloze kot tvorilca hidrofilnih ogrodnih tablet| Functionality-related characteristics of hypromellose used as a matrix forming agent|"},"dc:description":[{"@xml:lang":"sl","#text":"Pharmaceutical excipents are essential components of dosage forms. The key physico-chemical properties of functional excipients should be identified, and the influence of their variability on the properties of the final dosage form should be evaluated during the de- velopment phase. The European Pharmacopeia (6.1) has introduced a nonmandatory functionality related characteristics (FRCs) sections in certain excipient monographs. Data obtained from literature and our results prove that FRCs sections are not only addi- tional testing, but they also contribute to the quality of a medicinal product and to the understanding which FRC parameter is critical for the intended use or intended formulation. Correct understanding and evaluation of physico-chemical characteristics of ex- cipients in pre-formulation study are critical for safe, non-toxic and effective medicine product"},{"@xml:lang":"sl","#text":"Pomožne snovi so bistvene sestavine farmacevtskih oblik. Zaradi tega je treba v fazi razvoja vsakega no- vega izdelka natančno proučiti njihove fizikalno-ke- mijske lastnosti in njihov vpliv na kakovost končnega izdelka. S tem namenom so v 6. dopolnilo (6.1) Ev- ropske farmakopeje njeni snovalci vključili novo splo- šno poglavje z naslovom S funkcionalnostjo povezane lastnosti (FRC lastnosti) pomožnih snovi. Predstavljeni literaturni podatki in rezultati lastnega proučevanja s funkcionalnostjo povezanih lastnosti na primeru hi- promeloze dokazujejo, da uvedeni FRC razdelki ne prinašajo zgolj dodatnega testiranja, ampak bistveno pripomorejo k pravilnemu razumevanju, katere FRC lastnosti posamezne pomožne snovi so kritične za nameravano uporabo v formulacijah. Pravilno razu- mevanje in ovrednotenje fizikalno-kemijskih lastnosti pomožnih snovi že v predformulacijskih študijah no- vega izdelka tako bistveno pripomorejo h kakovosti, varnosti in učinkovitosti zdravila"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-MHZDI69C","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-MHZDI69C"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-MHZDI69C/af77058e-2ed4-498c-b19b-4738a0bb50ad/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-MHZDI69C/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-MHZDI69C"}}}}